HR Execs on the Move

Intercept Pharmaceuticals

www.interceptpharma.com

 
We are a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive, non-viral liver diseases, including primary biliary cholangitis (PBC), nonalcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC) and biliary atresia. In a new age of liver disease treatment, our team is developing vital therapies to meet the needs of those living with progressive, non-viral liver disease. We are committed to improving patients` lives and addressing the liver community`s most pressing needs. Our corporate headquarters is located in New York, and we have additional offices in San Diego, London and Perugia.
  • Number of Employees: 250-1000
  • Annual Revenue: $250-500 Million

Executives

Name Title Contact Details
Douglas Maneval
Executive Director R&D Quality Profile
Antonio Civitarese
Sr Director, Director of Clinical Research and Development Profile
Michelle Berrey
President R&D and Chief Medical Officer Profile
Dick Lancaster
Vice President, Product Development Profile
Andrew Saik
Chief Financial Officer Profile

Jobs

Director, Human Resources

Intercept Pharmaceuticals San Diego, CA
Accountable for developing and implementing U.S. Regional (San Diego office) HR strategy, in alignment with global HR direction & strategy, to ensure delivery of HR support that enables the U.S. organization to meet or exceed short- and long-term business objectives. While partnering closely with U.S. business operations leaders, areas of ...

Similar Companies

Vallon Pharmaceuticals

Vallon is a biopharmaceutical company focused on the development and commercialization of novel abuse-deterrent medications for CNS disorders. $VLON

Lotus Pharmaceuticals

Lotus Pharmaceuticals, Inc. is a Boca Raton, FL-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

XORTX

XORTX Therapeutics Inc. is a BioPharmaceutical company focused on developing innovative therapies to treat progressive kidney disease. XORTX has lead programs to develop treatments for progressive kidney disease due to diabetes, diabetic nephropathy, and polycystic kidney disease. Secondary programs focus on developing therapies for health consequences that accompany pre-diabetes, diabetes and cardiovascular disease.

RenalytixAI

Renalytix AI plc (LSE AIM: RENX) is a leading developer of artificial intelligence-enabled clinical diagnostic solutions for kidney disease.